This study was completed with the participation of the Trial 127 Study Investigators: Scott Aaronson, Sheppard Pratt Health Care System, Baltimore; Gustavo Alva, UCI Medical Center, Orange, Calif.; Todd Antin, nTouch Research, Decatur, Ga.; Valerie Arnold, Clinical NeuroScience, Memphis, Tenn.; Roberta Ball, CNS Research Institute, Philadelphia; Benny Barnhart, Grayline Clinical Drug Trials, Wichita Falls, Kans.; Jason Baron, MedLabs Research of Houston Inc., Houston; Bijan Bastani, North Coast Clinical Trials, Beachwood, Ohio; Louise Beckett, IPS Research Company, Oklahoma City; Ari Kiev, Social Psychiatry Research Institute, New York; Gary J. Booker, Shreveport, La.; Guy E. Brannon, Brentwood Research Institute, Shreveport, La.; Vicki Burdine, Valle Vista Health System, Greenwood, Ind.; Jose M. Canive, New Mexico VA Health Care System, Albuquerque; John Carman, Carman Research, Smyrna, Ga.; James C.-Y. Chou, Bellevue Hospital Center, New York; Andrew J. Cutler, CORE Research, Maitland, Fla.; Bernadette D’Souza, Midwest Clinical Research Center, Dayton, Ohio; Brad Diner, Arkansas Psychiatric Clinic, Little Rock; Carlos Figueroa, Advanced Psychiatric Group, Pasadena, Calif.; Donald J. Garcia, Jr., Futuresearch, Austin, Tex.; Thomas Gazda, Meadowbrook Research, Scottsdale, Ariz.; Ram Gopalan, Comprehensive Neuroscience of Northern Virginia, Arlington; James Grimm, Oregon Center for Clinical Investigations, Salem; Mahlon Hale, New Britain General Hospital, New Britain, Conn.; Mark Hamner, Ralph H. Johnson VA Medical Center, Charleston, S.C.; Linda Harper, Clinical NeuroScience Solutions, Orlando, Fla.; Barbara Harris, PsyPharma Clinical Research, Phoenix; Howard Hassman, CNS Research Institute, Clementon, N.J.; Naveed Iqbal, Soundview Throggs Neck Mental Health Center, New York; George Joseph, Clinical NeuroScience Solutions, Jacksonville, Fla.; Jasbir Kang, CrossRoads Counseling and Consulting Associates, Moon Township, Pa.; Zerrin Emel Kayatekin, Berkshire Medical Center, Pittsfield, Mass.; Paul Keck, University of Cincinnati Medical Center, Cincinnati; Arifulla Khan, Northwest Clinical Research, Bellevue, Wash.; Esha Khoshnu, Northern New Jersey Medical Institute, West Caldwell; Mary Ann Knesevich, University Hills Clinical Research, Irving, Tex.; James Knutson, Eastside Therapeutic Resource, Kirkland, Wash.; Mark Lerman, Comprehensive NeuroScience, Hoffman Estates, Ill.; Azfar Malik, Psych Care Consultants Research, St. Louis; David Marks, Optimum Health Services, La Mesa, Calif.; Joseph McEvoy, John Umstead Hospital, Butner, N.C.; Denis Mee-Lee, Hawaii Clinical Research Center, Honolulu; Charles Merideth, Affiliated Research Institute, San Diego; Alexander L. Miller, University of Texas Health Science Center at San Antonio; Janice L. Miller, Clinical Neuroscience Solutions, West Palm Beach, Fla.; Raymond Manning, CNRI-LA, LLC, Pico Rivera, Calif.; Rakesh Ranjan, Rakesh Ranjan and Associates, Inc., Medina, Ohio; Alfredo Rivera, Community Research, Cincinnati; Leon Rosenberg, Center for Emotional Fitness, Moorsetown, N.J.; Leon Rubenfaer, Pioneer Pharmaceutical Research, New Baltimore, Mich.; David Sack, Institute of Psychopharmacology Research, Cerritos, Calif.; Mary C. Shemo, Psychiatric Alliance of the Blue Ridge, Charlottesville, Va.; Raj Shiwach, The Cedars Hospital, DeSoto, Tex.; James Stevenson, Addiction and Psychiatric Medicine Research, Morgantown, W.V.; Tram Tran-Johnson, CNRI–San Diego, San Diego; Nicholas Vatakis, Social Psychiatry Research Institute, New York; David P. Walling, CNS Network, Garden Grove, Calif.; Richard Weisler, Richard Weisler M.D. and Associates, Raleigh, N.C.; Trisha Suppes, UT Southwestern Medical Center at Dallas; Raj Rajani, Behavioral and Medical Research, Anaheim, Calif.; H.E. Logue, Birmingham Psychiatry Pharmaceutical Studies, Birmingham, Ala.; David E. Linden, Linden Research Consultants, Oklahoma City; David Miller, Friends Hospital, Philadelphia; Murray Rosenthal, Healthquest Clinical Trials, San Diego; Gene R. Flick, Medisphere Medical Research, Evansville, Ind.; Norman E. Rosenthal, Capital Clinical Research Associates, Rockville, Md.; Anantha Shekhar, Larue D. Carter Memorial Hospital, Indianapolis; Kashinath G. Yadalam, Lake Charles Clinical Trials, Lake Charles, La.; Dwight St. Clair, Heartland Research Associates, Wichita, Kans.; Georgia Jones, Medex Healthcare Research, St. Louis; John Duffy, APEX Research Institute, Santa Ana, Calif.; John H. Gilliam, International Clinical Research Associates, Richmond, Va.; Michael D. Banov, Northwest Behavioral Research Center, Marietta, Ga.; Michael G. Dempsey, Albuquerque Neuroscience, Inc., Albuquerque; Mark D. Fossey, University of Oklahoma at Tulsa; Robert Levine, Neuropsych Research Associates, New York; Mohammed Abdul Bari, Synergy Research, National City, Calif.; Robert A. Riesenberg, Atlanta Center for Medical Research, Atlanta; John M. Zajecka, Rush University Medical Center, Chicago; Richard W. Brown, Hartford Research Group, Cincinnati; David Feifel, San Diego Medical Center, San Diego; Richard L. Gibson, New Orleans Center for Clinical Research, New Orleans; Mark T. Schreiber, International Clinical Research Associates, Virginia Beach, Va.; Valentin Isacescu, Optimum Health Services, Oceanside, Calif.; Joachim Raese, Behavioral Health 2000, Riverside, Calif.; Cosme Lozano, Jr., Center for Neuropsychiatric Development, Joliet, Ill.; Stephen M. Mohaupt, California Clinical Trials, Culver City; Alan H. Rosenbaum, Psychopharmacology Research Corporation, Farminton Hills, Mich.; Franco Sicuro, Millennium Psychiatric Associates, St. Louis; Richard M. Steinbook, University of Miami/Department of Psychiatry, Miami, Fla.; Peter Hauser, Portland VA Medical Center, Portland, Ore.; Craig S. Risch, University of California, San Francisco; Andrew Winokur, University of Connecticut Health Center, Farmington; Cary J. Kohlenberg, Independent Psychiatric Consultants, Waukesha, Wisc.